Literature DB >> 26076769

Iron sucrose-labeled human mesenchymal stem cells: in vitro multilineage capability and in vivo traceability in a lapine xenotransplantation model.

Nikolaos Papadimitriou1,2, Susann Li3, Helena Barreto Henriksson1,2.   

Abstract

For evaluation of cell therapy applications, it is of interest to be able to trace and observe cellular distribution of the transplanted cells. The aim with the study was to examine viability, traceability, and multilineage capability of iron sucrose-labeled mesenchymal stem cells (MSCs) after transplantation into lapine intervertebral discs (IVDs). MSCs were collected from three human donors, age 31-50 years, and IVDs from 12 rabbits, age 3 months. MSCs were isolated from the bone marrow and cultured using standard protocols. Iron sucrose labeling of MSCs was performed in Dulbecco's Modified Eagle's Medium-low glucose with Venofer(®). The iron sucrose-labeled MSCs were differentiated into the adipogenic, osteogenic, and chondrogenic lineages. Results were evaluated using Oil red, von Kossa, Alcian blue, and collagen II (immunohistochemistry). For the animal experiments, iron sucrose-labeled MSCs and nonlabeled MSCs were injected into lapine IVDs (LI-LIV level). After transplantation, at the time points of 1 and 3 months, IVDs were collected and cells were analyzed for cell viability (fluorescence-activated cell sorting). The lapine IVDs were collected and examined for presence of cells positive for iron deposits using Berliner blue staining. Differentiation of the iron sucrose-labeled MSCs into adipogenic (lipid droplets), osteogenic (calcium deposits), and chondrogenic lineage (proteoglycan/collagen II accumulation) (3/3 donors) was observed in vitro. After transplantation, the mean cell viability for iron-labeled MSCs/IVD cells was 99%, for nonlabeled MSCs/IVD cells was 95%, and for control IVD cells was 99% at a time point of 1 month. At a time point of 3 months, mean cell viability was 73% for iron sucrose-labeled MSCs/IVD cells, for nonlabeled MSCs/IVD cells was 77%, and for control IVD cells was 98%. At the time point of 1 month, cells positive for iron deposits were detected sparsely distributed in IVDs (tissue sections) in 4/4 animals and at the time point of 3 months in 4/4 animals. The results indicate that iron sucrose can be used as a cell tracer with a stable detection potential in tissues (histologies). This may be an important evaluation tool for understanding stem cell distribution/function after transplantation into degenerated cartilaginous tissues.

Entities:  

Mesh:

Year:  2015        PMID: 26076769     DOI: 10.1089/scd.2015.0140

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  5 in total

1.  Intradiscal Injection of Iron-Labeled Autologous Mesenchymal Stromal Cells in Patients With Chronic Low Back Pain: A Feasibility Study With 2 Years Follow-Up.

Authors:  Nikolaos Papadimitriou; Hanna Hebelka; Daphne Hingert; Adad Baranto; Helena Barreto Henriksson; Anders Lindahl; Helena Brisby
Journal:  Int J Spine Surg       Date:  2021-12

2.  Using iron sucrose-labeled adipose-derived mesenchymal stem cells in 1.5 and 3 T MRI tracking: An in vitro study.

Authors:  Paween Tangchitphisut; Narongrit Srikaew; Sith Phongkitkarun; Suphaneewan Jaovisidha; Tulyapruek Tawonsawatruk
Journal:  Heliyon       Date:  2020-08-01

3.  The Effect of Different Routes of Injection of Bone Marrow Mesenchymal Stem Cells on Parotid Glands of Rats Receiving Cisplatin: A Comparative Study.

Authors:  Eman Hany; Mohammed A Sobh; Mazen T Abou ElKhier; Heba M ElSabaa; Ahmed R Zaher
Journal:  Int J Stem Cells       Date:  2017-11-30       Impact factor: 2.500

Review 4.  Cell sources proposed for nucleus pulposus regeneration.

Authors:  Rebecca J Williams; Marianna A Tryfonidou; Joseph Wiliam Snuggs; Christine Lyn Le Maitre
Journal:  JOR Spine       Date:  2021-11-24

Review 5.  Iron Oxide Nanoparticles in Mesenchymal Stem Cell Detection and Therapy.

Authors:  Kosha J Mehta
Journal:  Stem Cell Rev Rep       Date:  2022-02-01       Impact factor: 6.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.